NUP210
Nuclear pore membrane glycoprotein 210
Also known as: FLJ22389, GP210, KIAA0906, PO210_HUMAN, POM210
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8TEM1
- Gene
- NUP210
- Ensembl
- ENSG00000132182
- Chromosome
- 3
- Canonical length
- 1887 aa
- Protein class
- Metabolic proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
The nuclear pore complex is a massive structure that extends across the nuclear envelope, forming a gateway that regulates the flow of macromolecules between the nucleus and the cytoplasm. Nucleoporins are the main components of the nuclear pore complex in eukaryotic cells. The protein encoded by this gene is a membrane-spanning glycoprotein that is a major component of the nuclear pore complex. Multiple pseudogenes related to this gene are located on chromosome 3. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
1887 residues, UniProt reviewed canonical sequence.
>Q8TEM1|NUP210
1 MAARGRGLLL LTLSVLLAAG PSAAAAKLNI PKVLLPFTRA TRVNFTLEAS EGCYRWLSTR
61 PEVASIEPLG LDEQQCSQKA VVQARLTQPA RLTSIIFAED ITTGQVLRCD AIVDLIHDIQ
121 IVSTTRELYL EDSPLELKIQ ALDSEGNTFS TLAGLVFEWT IVKDSEADRF SDSHNALRIL
181 TFLESTYIPP SYISEMEKAA KQGDTILVSG MKTGSSKLKA RIQEAVYKNV RPAEVRLLIL
241 ENILLNPAYD VYLMVGTSIH YKVQKIRQGK ITELSMPSDQ YELQLQNSIP GPEGDPARPV
301 AVLAQDTSMV TALQLGQSSL VLGHRSIRMQ GASRLPNSTI YVVEPGYLGF TVHPGDRWVL
361 ETGRLYEITI EVFDKFSNKV YVSDNIRIET VLPAEFFEVL SSSQNGSYHR IRALKRGQTA
421 IDAALTSVVD QDGGVHILQV PVWNQQEVEI HIPITLYPSI LTFPWQPKTG AYQYTIRAHG
481 GSGNFSWSSS SHLVATVTVK GVMTTGSDIG FSVIQAHDVQ NPLHFGEMKV YVIEPHSMEF
541 APCQVEARVG QALELPLRIS GLMPGGASEV VTLSDCSHFD LAVEVENQGV FQPLPGRLPP
601 GSEHCSGIRV KAEAQGSTTL LVSYRHGHVH LSAKITIAAY LPLKAVDPSS VALVTLGSSK
661 EMLFEGGPRP WILEPSKFFQ NVTAEDTDSI GLALFAPHSS RNYQQHWILV TCQALGEQVI
721 ALSVGNKPSL TNPFPAVEPA VVKFVCAPPS RLTLAPVYTS PQLDMSCPLL QQNKQVVPVS
781 SHRNPRLDLA AYDQEGRRFD NFSSLSIQWE STRPVLASIE PELPMQLVSQ DDESGQKKLH
841 GLQAILVHEA SGTTAITATA TGYQESHLSS ARTKQPHDPL VPLSASIELI LVEDVRVSPE
901 EVTIYNHPGI QAELRIREGS GYFFLNTSTA DVVKVAYQEA RGVAMVHPLL PGSSTIMIHD
961 LCLVFPAPAK AVVYVSDIQE LYIRVVDKVE IGKTVKAYVR VLDLHKKPFL AKYFPFMDLK
1021 LRAASPIITL VALDEALDNY TITFLIRGVA IGQTSLTASV TNKAGQRINS APQQIEVFPP
1081 FRLMPRKVTL LIGATMQVTS EGGPQPQSNI LFSISNESVA LVSAAGLVQG LAIGNGTVSG
1141 LVQAVDAETG KVVIISQDLV QVEVLLLRAV RIRAPIMRMR TGTQMPIYVT GITNHQNPFS
1201 FGNAVPGLTF HWSVTKRDVL DLRGRHHEAS IRLPSQYNFA MNVLGRVKGR TGLRVVVKAV
1261 DPTSGQLYGL ARELSDEIQV QVFEKLQLLN PEIEAEQILM SPNSYIKLQT NRDGAASLSY
1321 RVLDGPEKVP VVHVDEKGFL ASGSMIGTST IEVIAQEPFG ANQTIIVAVK VSPVSYLRVS
1381 MSPVLHTQNK EALVAVPLGM TVTFTVHFHD NSGDVFHAHS SVLNFATNRD DFVQIGKGPT
1441 NNTCVVRTVS VGLTLLRVWD AEHPGLSDFM PLPVLQAISP ELSGAMVVGD VLCLATVLTS
1501 LEGLSGTWSS SANSILHIDP KTGVAVARAV GSVTVYYEVA GHLRTYKEVV VSVPQRIMAR
1561 HLHPIQTSFQ EATASKVIVA VGDRSSNLRG ECTPTQREVI QALHPETLIS CQSQFKPAVF
1621 DFPSQDVFTV EPQFDTALGQ YFCSITMHRL TDKQRKHLSM KKTALVVSAS LSSSHFSTEQ
1681 VGAEVPFSPG LFADQAEILL SNHYTSSEIR VFGAPEVLEN LEVKSGSPAV LAFAKEKSFG
1741 WPSFITYTVG VLDPAAGSQG PLSTTLTFSS PVTNQAIAIP VTVAFVVDRR GPGPYGASLF
1801 QHFLDSYQVM FFTLFALLAG TAVMIIAYHT VCTPRDLAVP AALTPRASPG HSPHYFAASS
1861 PTSPNALPPA RKASPPSGLW SPAYASHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NUP210 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 37 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 37 nTPM
- spleen: 31 nTPM
- thymus: 30 nTPM
- lymph node: 25 nTPM
- small intestine: 21 nTPM
- liver: 19 nTPM
Single-cell type
- erythrocyte progenitors: 180 nCPM
- monocyte progenitors: 150 nCPM
- b-cells: 112 nCPM
- megakaryocyte progenitors: 108 nCPM
- pdcs: 107 nCPM
- nk-cells: 95 nCPM
Immune cell
- gdT-cell: 3.7 nTPM
- memory CD8 T-cell: 3.3 nTPM
- MAIT T-cell: 2.9 nTPM
- plasmacytoid DC: 2.8 nTPM
- intermediate monocyte: 2.3 nTPM
- memory CD4 T-cell: 2.3 nTPM
Brain region
- medulla oblongata: 9.4 nTPM
- hypothalamus: 8.6 nTPM
- midbrain: 8.5 nTPM
- white matter: 8.4 nTPM
- cerebral cortex: 8.2 nTPM
- cerebellum: 8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NUP210.
Disease | ImmuneIEDB
Conditions an epitope on NUP210 was assayed in.
- melanoma T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against NUP210 are reported. Each links to that disease's full target list.
Showing 2 of 3 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for NUP210 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
66 publications
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
2008 · Hepatology · RCR 13.4 · 512 citations - Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.
2007 · Hepatology · RCR 7.5 · 276 citations - PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis.
2010 · J Autoimmun · RCR 3.2 · 104 citations - Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis.
1994 · Gastroenterology · RCR 3.1 · 89 citations - Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
2021 · Liver Int · RCR 2.9 · 35 citations
Show 20 more of 66 total
- The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system.
2025 · Dig Liver Dis · RCR 2.7 · 7 citations - Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients.
2009 · J Rheumatol · RCR 2.7 · 79 citations - Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis.
2007 · Hepatology · RCR 2.7 · 99 citations - Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
2024 · Immun Inflamm Dis · RCR 2.6 · 9 citations - Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis.
1996 · Hepatology · RCR 2.4 · 89 citations - Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210.
1993 · J Exp Med · RCR 2.1 · 77 citations - Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.
2003 · J Autoimmun · RCR 1.9 · 73 citations - Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease.
2013 · Autoimmunity · RCR 1.9 · 52 citations - Antinuclear antibodies specific for primary biliary cirrhosis.
2003 · Autoimmun Rev · RCR 1.8 · 79 citations - Clinical significance of autoantibodies in primary biliary cirrhosis.
2014 · Semin Liver Dis · RCR 1.7 · 49 citations - Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.
2020 · Am J Gastroenterol · RCR 1.7 · 27 citations - Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis.
2007 · Hepatology · RCR 1.4 · 50 citations - Autoantibodes to GP210 are a metric for UDCA responses in primary biliary cholangitis.
2024 · J Transl Autoimmun · RCR 1.4 · 5 citations - Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
2023 · Clin Chim Acta · RCR 1.3 · 7 citations - Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis.
2019 · Hepatology · RCR 1.3 · 29 citations - Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay.
2015 · Clin Chim Acta · RCR 1.1 · 28 citations - The value of antinuclear antibodies in primary biliary cirrhosis.
2008 · Clin Exp Med · RCR 1.1 · 36 citations - Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease.
2009 · Clin Gastroenterol Hepatol · RCR 1.1 · 35 citations - Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC.
2010 · Hepatol Res · RCR 1.1 · 44 citations - Risk factors and prediction of long-term outcome in primary biliary cirrhosis.
2011 · Intern Med · RCR 1.1 · 32 citations
Reference: T cellIEDB
3 publications
- Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
2024 · Blood · RCR 1.5 · 14 citations - Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
2019 · Front Immunol · RCR 0.9 · 28 citations - High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.
2011 · PLoS One · RCR 0.6 · 29 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.73
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.78
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Bacterial Ig-like domain, group 2
- Invasin/intimin cell-adhesion fragments
- Nuclear pore membrane glycoprotein 210-like
- NUP210, Ig-like domain 15
- NUP210, C-terminal Ig-like domain
- NUP210, Ig-like domain 1
- NUP210, Ig-like domain 2
- NUP210, Ig-like domain 3
- NUP210, Ig-like domain 7
- NUP210, fourth Ig-like domain
- NUP210, Ig-like domain 6
- NUP210, Ig-like domain 9
- NUP210, Ig-like domain 16
- NUP210, Ig-like domain 13
- Bacterial Ig-like domain (group 2)
- NUP210 Ig-like domain
- NUP210 Ig-like domain 15
- NUP210 Ig-like domain 7
- NUP210 Ig-like domain 3
- NUP210 Ig-like domain 1
- NUP210 Ig-like domain 2
- NUP210, Ig-like domain 9
- NUP210-like, Ig-like domain 6
- NUP210 forth Ig-like domain
- NUP210-like, Ig-like domain 16
- NUP210 Ig-like domain 13
- NUP210 Ig-like domain 5
- NUP210 Ig-like domain 14
- NUP210 Ig-like domain 8
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NUP210 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NUP210 as an antibody target. Whether an autoantibody or antibody against NUP210 could matter depends on whether native NUP210 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NUP210 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NUP210 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...